Drugs / Inaticabtagene autoleucel
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07091370 | Dec 2025 → Sep 2026 overdue | autoimmune hemolytic anemia, cold type | Juventas Cell Therapy Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06826430 | Mar 2025 → Mar 2026 overdue | autoimmune thrombocytopenia | Juventas Cell Therapy Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06777264 | Jan 2025 → Dec 2026 expected | B-cell acute lymphoblastic leukemia | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06718244 | Dec 2024 → Dec 2029 expected | acute lymphoblastic leukemia | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06608732 | Aug 2024 → Jul 2028 expected | B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inaticabtagene autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06718244 ↗ |
| Known as | Inaticabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314746 ↗ |
| Modality | Cell therapy | “commercial CD19 CAR-T product” NCT06777264 ↗ |
| Route | Intravenous | “transfusioned intravenously” NCT06777264 ↗ |
| Target | CD19 | “CD19 CAR-T cells” NCT06777264 ↗ |